Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Christopher E. Gaw, Henry A. Spiller, Jason L. Russell, Thiphalak Chounthirath & Gary A. Smith. (2018) Evaluation of dose and outcomes for pediatric vilazodone ingestions. Clinical Toxicology 56:2, pages 113-119.
Read now
Read now
Roger S McIntyre. (2017) The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatric Disease and Treatment 13, pages 2913-2919.
Read now
Read now
Susan L. McElroy, Anna I. Guerdjikova, Nicole Mori & Paul E. Keck. (2016) Managing comorbid obesity and depression through clinical pharmacotherapies. Expert Opinion on Pharmacotherapy 17:12, pages 1599-1610.
Read now
Read now
Zeyad T. Sahli, Pradeep Banerjee & Frank I. Tarazi. (2016) The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder. Expert Opinion on Drug Discovery 11:5, pages 515-523.
Read now
Read now
Philip F Saltiel & Daniel I Silvershein. (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatric Disease and Treatment 11, pages 875-888.
Read now
Read now
Theresa A Zesiewicz & Pablo Martinez-Martin. (2013) Effects of rotigotine transdermal system on non-motor symptoms in Parkinson’s disease: an overview. Expert Review of Neurotherapeutics 13:12, pages 1329-1342.
Read now
Read now
Lee A Dawson. (2013) The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?. Expert Opinion on Drug Discovery 8:12, pages 1529-1539.
Read now
Read now
Articles from other publishers (1)
Xiu-Rong Hu, Jia-Li Ye & Jian-Ming Gu. (2016) Crystal structure of vilazodone hydrochloride methanol monosolvate. Acta Crystallographica Section E Crystallographic Communications 72:12, pages 1783-1785.
Crossref
Crossref